On September 14, 2026, Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447 in patients with Idiopathic Pulmonary Fibrosis (IPF). The study demonstrated a favorable safety profile at the 4.5 mg twice-daily dose and confirmed robust target engagement of ALK5 via pSMAD3 reduction exceeding 50%. Pharmacokinetic data showed efficient lung restriction with low systemic exposure. The company submitted a Clinical Trial Application for the Phase 2 INSPIRIA study, which will enroll approximately 120 IPF patients in a randomized, double-blind trial evaluating forced vital capacity changes over 24 weeks. Agomab intends to initiate this study before year-end across European sites. Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibro-inflammatory diseases.

AgomAb Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive directors, with shareholder approval scheduled for a Special General Meeting on September 11, 2026. The company also plans to hold an Extraordinary General Shareholders’ Meeting to consolidate and split outstanding pre-IPO subscription rights at a ratio of 21.6450216450216-to-1, aligning them with the share structure established during its February 2026 IPO. This adjustment simplifies management by ensuring each subscription right entitles holders to subscribe for one new ordinary share while proportionally adjusting exercise prices. AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases.

AgomAb Therapeutics NV reported financial results for the six months ended June 30, 2026, and confirmed its business outlook. The company achieved a cash position of €252 million as of June 30, 2026, including $208 million in gross proceeds from its February 2026 IPO, which extends the cash runway into the first half of 2029. Research and development expenses were €23.0 million, while general and administrative expenses rose to €12.2 million due to one-off IPO costs. The net loss for the period was €31.0 million compared to €26.9 million in the prior year period. Clinically, AgomAb aligned with the FDA on the design of the NOV-ERA Phase 2b study for ontunisertib in Fibrostenosing Crohn’s Disease and expects to initiate this trial in the second half of 2026. Topline data from the long-term extension study of ontunisertib and a Phase 1b cohort with AGMB-447 in Idiopathic Pulmonary Fibrosis are expected in the coming months. AgomAb is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases.